Fig. 6. The FGF10-FGFR2b complex shows greater binding to purified intact HUAEC perlecan than FGF10 or FGFR2b alone, and binding of the complex is reduced by heparanase treatment. (A) SPR analysis of FGF10, FGFR2b, and FGF10-FGFR2b complex binding to intact perlecan. Proteins were diluted in HBS-P containing 0.1 µg/ml heparin. (B) SPR analysis of FGF10-FGFR2b binding to perlecan before and after heparanase treatment. Heparanase (5 µg/ml at 5 µl/minute) was applied to the chip surface. RU, response units.